Your browser doesn't support javascript.
loading
Cardiorenal Syndrome in Right Heart Failure Due to Pulmonary Arterial Hypertension-The Right Ventricle as a Therapeutic Target to Improve Renal Function.
Ichimura, Kenzo; Gross, Adam; Mathew, Roy O; Salman, Loay; Reddy, Sushma; Spiekerkoetter, Edda; Sidhu, Mandeep S.
Afiliación
  • Ichimura K; Department of Medicine, Division of Pulmonary, Allergy and Critical Care, Stanford University, 1701 Page Mill Road, Palo Alto, CA, 94304, USA. kennzo@stanford.edu.
  • Gross A; Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford University, Stanford, CA, 94305, USA. kennzo@stanford.edu.
  • Mathew RO; Cardiovascular Institute, Stanford University, Stanford, CA, 94305, USA. kennzo@stanford.edu.
  • Salman L; Albany Medical College, Albany, NY, 12208, USA.
  • Reddy S; Department of Medicine, Loma Linda VA Health Care System, Loma Linda, CA, 92357, USA.
  • Spiekerkoetter E; Division of Nephrology, Department of Medicine, Albany Medical College, Albany, NY, 12208, USA.
  • Sidhu MS; Cardiovascular Institute, Stanford University, Stanford, CA, 94305, USA.
Article en En | MEDLINE | ID: mdl-38847906
ABSTRACT
Cardiorenal syndrome (CRS) due to right ventricular (RV) failure is a disease entity emerging as a key indicator of morbidity and mortality. The multifactorial aspects of CRS and the left-right ventricular interdependence complicate the link between RV failure and renal function. RV failure has a direct pathophysiological link to renal dysfunction by leading to systemic venous congestion in certain circumstances and low cardiac output in other situations, both leading to impaired renal perfusion. Indeed, renal dysfunction is known to be an independent predictor of mortality in patients with pulmonary arterial hypertension (PAH) and RV failure. Thus, it is important to further understand the interaction between the RV and renal function. RV adaptation is critical to long-term survival in patients with PAH. The RV is also known for its remarkable capacity to recover once the aggravating factor is addressed or mitigated. However, less is known about the renal potential for recovery following the resolution of chronic RV failure. In this review, we provide an overview of the intricate relationship between RV dysfunction and the subsequent development of CRS, with a particular emphasis on PAH. Additionally, we summarize potential RV-targeted therapies and their potential beneficial impact on renal function.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Cardiovasc Drugs Ther Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Cardiovasc Drugs Ther Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article